Investor Presentaiton

III Key Investment Highlights 5 Resilient Supply Chain Highly diversified supplier/client base significantly mitigating supply chain risks Diversified Geographical Presence NORTH SINAL Alexandria 14.6% Cairo & Canal 31.5% Minimal Supplier Concentration Sanofi Aventis 7% Amoun 5% Expansive SKUs Coverage Distributed by ISP 96.5% MATRUH GIZA MINYA . ASYUT CAIRO SOUTH 944 SCHAG NEW VALLEY CENA LUKOR Upper Egypt 25.2% % of Sales Novartis 4% Mina Pharm 3% Glaxo Smith Kline 3% % of Market Sales 26 Minimal operational risk 62 sites with 62 lifetime licenses Delta 28.7% Low client concentration risk due to small number of pharmacy chains in Egypt Cairo & Canal region has the highest sales contribution due to higher purchasing power Others 79% $ No FX Risk Minimal supplier concentration with the top five supplier representing less than 25% of sales Not Distributed by ISP 3.5% Product portfolio covers 85% of the SKUs available in the market, collectively representing 93% of the market sales value U NOVARTIS PHARMACEUTICALS Multiple Contracts with Key Suppliers gsk Pfizer AstraZeneca PHARCO PHARMACEUTICALS MUP Medical Union Pharmaceuticals SERVIER SEDICO ய سد " يكو SANOFI Abbott Roche MINAPHARM AIKMA Marcyrl QUALITY GNP EIPICO AMOUN EVAPHARMA Securing Your Health ibnsinapharma Source: IMS Health; Company Management No SKU Concentration (Each SKU ≤ 0.5% of sales) map 18

View entire presentation